Continuous Adductor Canal Infusion vs. Single-injection Adductor Canal Block for Total Knee Arthroplasty
Multimodal Analgesia for Unilateral Total Knee Arthroplasty: Impact of Continuous Adductor Canal Infusion Combined With NSAID vs. Intravenous Morphine Patient-controlled Analgesia Combined With Single-injection Adductor Canal Block
1 other identifier
interventional
80
1 country
1
Brief Summary
Multimodal analgesia (MMA) has been endorsed to improve postoperative analgesia and functional activity after surgery, and integrating regional analgesia to reduce the consumption of opioid has also been used in postoperative pain management. The investigator try to find a better combination of MMA for postoperative analgesia and functional recovery for patients receiving TKA in Taiwan, therefore the effect of single-injection and continuous infusion of peripheral nerve block is compared in patient undergoing unilateral TKA. The investigators hypothesize that continuous adductor canal infusion is as effective as single-injection adductor canal block for postoperative pain relief under intravenous PCA after TKA surgery. Based on that, the investigators conduct this prospective, randomized controlled trial to examine our hypothesis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 21, 2019
CompletedFirst Submitted
Initial submission to the registry
May 23, 2022
CompletedFirst Posted
Study publicly available on registry
January 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedMarch 10, 2023
March 1, 2023
4 years
May 23, 2022
March 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (10)
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Baseline (day of admission)
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 2 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 8 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 24 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 36 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 48 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 60 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Hour 72 after surgery
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
1 day of discharge
Change in Pain scores at rest and motion
Assess the pain intensity with numerical rating scale both at rest and motion in each knee. A 11 point (0-10) numerical rating scale defines 0 as no pain and 10 as the worst pain imaginable.
Month 3 after surgery
Secondary Outcomes (39)
Rehabilitation physiotherapy: Knee flexion angle
Baseline (day of admission)
Rehabilitation physiotherapy: Knee flexion angle
Hour 24 after surgery
Rehabilitation physiotherapy: Knee flexion angle
Hour 72 after surgery
Rehabilitation physiotherapy: Knee flexion angle
1 Day of discharge
Rehabilitation physiotherapy: Knee flexion angle
Month 3 after surgery
- +34 more secondary outcomes
Study Arms (2)
Single-injection ACB combined with IV-PCA morphine
ACTIVE COMPARATORAllocation of which participant is to receive single-injection adductor canal block combined with intravenous morphine patient-controlled analgesia (IV-morphine PCA) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, adductor canal block will be performed by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following skin infiltration, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through a 3-inch, 23-gauge, short bevel block needle. Finally, the IV-morphine PCA will be connected to the intravenous catheter of the patient for postoperative pain management.
Continuous adductor canal infusion combined with intravenous NSAID
ACTIVE COMPARATORAllocation of which participant is to receive continuous adductor canal infusion in combination with intermittent intravenous non-steroidal anti-inflammatory drug (NSAID) is determined by randomization, using a computer-generated random sequence and opaque sealed envelopes. After completion of the TKA surgery and surgical suturing, a peripheral nerve catheter will be implanted into adductor canal by an anesthesiologist. Under ultrasound guidance, the femoral artery and the saphenous nerve are identified in the middle one-third of the thigh, deep to the sartorious muscle in the adductor canal. The sartorious and adductor muscles form the roof and the floor of the canal, respectively. Following the peripheral nerve catheter is implanted, 20 mL of 0.25% bupivacaine with 1:400000 epinephrine is injected through the catheter. Intravenous tenoxicam 20 mg for a total amount of 3 doses at 24-hour interval after surgery will be added in the postoperative pain management.
Interventions
Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
For the functional assessment both before and after TKA surgery.
Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of knee osteoarthritis
- Must be aged between 20 to 90 years old
- Must be scheduled for unilateral total knee arthroplasty surgery
- Must agree to enroll into the clinical trial and have signed the written informed consent
You may not qualify if:
- American Society of Anesthesiologists physical status class IV-V
- Elevated liver enzymes or liver failure
- Renal dysfunction (serum creatinine level ≥ 1.5 mg/dL)
- Cardiac failure
- Organ transplantation recipient
- Stroke
- Major neurological deficit with lower extremity muscle weakness
- Sensory and motor disorders in lower limb
- Coagulopathy or thrombocytopenia
- Previous drug dependency
- Patients who used illicit drugs within six months
- Chronic use of opioids
- Allergy to local anesthetics and drug used in experiment
- Inability to walk independently
- Inability to comprehend pain assessment
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Hsu Ma, MD, PhD
Institutional Review Board, Taipei Veterans General Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2022
First Posted
January 3, 2023
Study Start
May 21, 2019
Primary Completion
May 31, 2023
Study Completion
June 30, 2023
Last Updated
March 10, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share